Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 756 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System, iStent inject; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dothan, Alabama • Vineland, New Jersey

Conditions: Glaucoma
Interventions: TEMPO iMOvifa; Diagnostic Test
Lead sponsor: Cape Fear Eye Institute; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Glaucoma, Ocular Hypertension
Interventions: BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Week to 5 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cataract, Glaucoma
Interventions: disposable Deltran I pressure sensor; Diagnostic Test
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: No Treatment; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma
Interventions: Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy; Device · Drug
Lead sponsor: Aeon Astron Europe B.V.; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Rogers, Arkansas • Chicago, Illinois • Newark, New Jersey + 4 more

Conditions: Glaucoma
Interventions: Trabeculectomy, Ex-PRESS mini shunt; Procedure · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 7
States / cities: San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more

Conditions: Glaucoma
Interventions: Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT); Device
Lead sponsor: Twin Cities Eye Consultants; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Coon Rapids, Minnesota

Conditions: Glaucoma Open-Angle
Interventions: Glaucoma surgery; Device
Lead sponsor: PLU Ophthalmic; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more

Conditions: Glaucoma, Retinal Disease, Corneal Disease
Interventions: Nidek Mirante, Optovue RTVue XR Avanti, Optos P200DTx; Device
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 22 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Primary Open Angle Glaucoma, Cataract
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: EyeCheck, Traditional Tonometer (Goldmann and Tonopen); Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: HOCD; Device
Lead sponsor: Benjamin Frankfort, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Angle-Closure, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: standard of care, education; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma
Interventions: Diopsys NOVA; Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma
Interventions: Personalized eHealth Education & Motivational Interviewing; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Flint, Michigan • Ypsilanti, Michigan

Conditions: Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions: IRX-101, Control; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT); Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 5
States / cities: Petaluma, California • Tampa, Florida • New York, New York + 2 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide/Timolol; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Search by objective public record fields.

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

Glaucoma Screening

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma

Glaucoma Laser Assessment of Stability and Sustainability

A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma

Safety and Feasibility of the ELIOS System in POAG Patients

Agreement and Precision Study of the Nidek Mirante

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Reliability and Reproducibility of the Eye Check Tonometer

Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients

Assessing Ocular Surface Changes After Changing Glaucoma Medications

Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Screening and Intervention for Glaucoma and Eye Health Through Telemedicine

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

SOLX Titanium Sapphire Laser for Trabeculoplasty

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension